New Therapies

Opinion

Opinion: Price Controls Hurt Cancer Patients, Risk Future Innovation – Inside Sources

The U.S. Senate just announced legislation within Medicare Part D with the headline “lower prescription drug costs for beneficiaries living with cancer.” Behind this headline, with a further examination of this proposal, there are caution lights and red flags raised by cancer survivors like myself and patient-focused healthcare organizations. The problem is the government price

Scroll to Top